West Pharm Svcs Stock Price, News & Analysis

West Pharmaceutical Services reported a strong second quarter in 2021, with net sales of $723.6 million, a growth of 37.3%. Organic sales growth was 30.6%, and diluted EPS rose to $2.47, marking a 104% increase. The company raised its full-year 2021 net sales guidance to $2.760-$2.785 billion and adjusted-diluted EPS guidance to $8.05-$8.20. The growth was driven by demand for high-value product components, particularly related to COVID-19 vaccines. Operating cash flow reached $233.1 million, reflecting a 13.6% increase.

West Pharmaceutical Services (NYSE: WST) will announce its second-quarter 2021 financial results on July 29, 2021, prior to market opening. Following this, a conference call is scheduled for 9:00 a.m. Eastern Time featuring a discussion on results and business outlook. Interested participants can join the call by dialing 877-930-8295 (U.S.) or 253-336-8738 (International) with conference ID 3089097. An online archive will be accessible on the company’s website for future reference.

West Pharmaceutical Services (NYSE: WST), a leader in injectable drug administration solutions, will present at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 2:30 PM ET. A live broadcast of the event can be accessed on their website in the 'Investors' section. West has nearly 10,000 employees across 50 locations and generated over $2.15 billion in sales in 2020. The company is a trusted partner to drug developers, delivering over 40 billion components annually.

West Pharmaceutical Services has declared a third-quarter 2021 dividend of $0.17 per share, scheduled for payment on August 4, 2021, to shareholders recorded as of July 21, 2021. This dividend reflects the company's ongoing commitment to return value to its shareholders. Additionally, management will present a business overview at the Bank of America Securities 2021 Healthcare Conference on May 11, 2021, at 2:45 p.m. EDT. West generated over $2.15 billion in sales in fiscal year 2020.

West Pharmaceutical Services reported impressive Q1 2021 results with net sales of $670.7 million, a 36.5% year-over-year increase. Diluted EPS rose 101% to $1.99, while adjusted-diluted EPS climbed 103% to $2.05. The company has raised its full-year net sales guidance to $2.630 billion - $2.655 billion from a previous range of $2.500 billion - $2.525 billion. This growth is attributed to strong organic sales driven by demand for COVID-19 related products and robust performance in the Proprietary Product Segment.

West Pharmaceutical Services, a leader in injectable drug administration, will release its first-quarter 2021 financial results on April 29, 2021, before the market opens. A conference call to discuss these results will take place at 9:00 a.m. Eastern Time. Participants can join by dialing 877-930-8295 (U.S.) or 253-336-8738 (International), using Conference ID 4285757. The call will be available for live broadcast on their website and archived for later access until May 6, 2021.

West Pharmaceutical Services, traded under the ticker WST, will present virtually at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on March 24, 2021, at 10:00 AM ET. The presentation will be accessible via a live audio webcast on their website. West is known for providing high-quality injectable solutions and services, boasting nearly 10,000 employees and generating over $2.15 billion in sales in 2020. The company is headquartered in Exton, Pennsylvania, and is included in the Standard & Poor's 500 index.

West Pharmaceutical Services, Inc. (NYSE: WST) has announced a second-quarter 2021 dividend of $0.17 per share. This dividend will be paid on May 5, 2021, to shareholders recorded as of April 21, 2021. The company, which generated over $2.15 billion in sales in fiscal year 2020, is recognized as a leading provider of injectable solutions and services. With nearly 10,000 employees globally, West plays a crucial role in ensuring the safe delivery of vital medicines.

West Pharmaceutical Services reported strong Q4 and full-year 2020 results, with Q4 net sales of $580.2 million, a 23.3% increase, and full-year net sales of $2.147 billion, up 16.7%. Q4 diluted EPS rose 53.6% to $1.29, while full-year EPS jumped 42.4% to $4.57. The company forecasts 2021 net sales between $2.500 billion and $2.525 billion and EPS of $6.00 to $6.15. Strong sales growth was driven by the Biologics and Generics segments, particularly high-value product components for COVID-19.